Medication Overview
Tremfya (guselkumab) is an injectable prescription medication used primarily to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It works by targeting interleukin-23 (IL-23), a cytokine that plays a critical role in the inflammation and immune response associated with these conditions.
Who Should Consider Tremfya? Tremfya is suitable for adults who:
- Have moderate to severe plaque psoriasis and are candidates for systemic therapy or phototherapy.
- Suffer from active psoriatic arthritis.
How is Tremfya Administered? Tremfya is administered as a subcutaneous injection. The typical regimen involves an initial dose followed by a second dose four weeks later, and subsequent doses every eight weeks thereafter. Patients are usually trained by healthcare professionals on how to self-administer using a pre-filled syringe.
Important Information for Tremfya Users:
- How to Use: Follow your healthcare provider’s instructions for self-administering Tremfya injections.
- Storage: Store Tremfya in the refrigerator. Allow the medication to reach room temperature before injecting to minimize discomfort.
- Side Effects: Common side effects include injection site reactions, upper respiratory infections, and diarrhea. Serious side effects can include severe allergic reactions and potential infection. Report any severe or unusual symptoms to your healthcare provider.
- Monitoring: Regular medical check-ups and possibly lab tests are recommended to monitor your health and the medication’s effectiveness.
Medication Warnings
- Infections: Tremfya can weaken the immune system, increasing the risk of serious infections. Promptly report any signs of infection, such as fever, chills, or persistent cough, to your healthcare provider.
- Allergic Reactions: Seek immediate medical help if you experience symptoms like rash, hives, swelling of the face, or difficulty breathing.
- Vaccinations: Avoid live vaccines during treatment with Tremfya. Discuss your vaccination history with your healthcare provider.
Who Should and Shouldn’t Take Tremfya?
- Suitable Candidates:
- Adults with moderate to severe plaque psoriasis or active psoriatic arthritis who require targeted immunomodulatory treatment.
- Unsuitable Candidates:
- Individuals with severe, active infections.
- Patients with known hypersensitivity to guselkumab or any components of the product.
For more detailed information and personalized advice, consult your healthcare provider.
